Resolve Biosciences GmbH

https://www.resolve-biosciences.com

Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company’s proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program. Resolve Biosciences is privately held and headquartered in Monheim, Germany. *

	Start	2020-11-16 renamed
	Industry	spatial omics technology
	Industry 2	Molecular Cartography™ technology
	Person	Gammack, Jason T. (Ansa Biotechnologies 202402– CEO before Resolve Biosciences + Inscripta + Qiagen + Ingenuity Systems)
	Person 2	Schatz, Peer M. (Resolve BioSciences 202012 Chairman + Co-Founder before Qiagen 1993–201910 CEO RESIGNED 10/19)

	Region	Monheim
	Country	Germany
	Street	10 Alfred-Nobel-Str. Creative Campus Monheim, Gebäude A03
	City	40789 Monheim
	Tel	+49-2173-2975-200
		Address record changed: 2020-12-11

Basic data	Employees	n. a.

		* Document for »About Section«: Resolve Biosciences GmbH. (12/10/20). "Press Release: Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis". Monheim.

		Record changed: 2024-02-23